Accentia Biopharmaceuticals will begin enrolling patients for its Phase 3 study of SinuNase™ in November and will include patients with severe chronic sinusitis refractory to sinus surgery. The Company believes that SinuNase, which has been Fast Tracked by the Food and Drug Administration (FDA), is the first product candidate to be in a Phase 3 trial for chronic sinusitis. Despite the fact that there are 31 million affected U.S. patients, and that chronic sinusitis is by far the most common chronic respiratory disease with a market twice the size of asthma, there is currently no approved prescription pharmaceutical for chronic sinusitis.
If this takes off, it will make BILLIONS! I need it right now with these crazy Santa Ana winds!
ABPI Pharmaceuticals is trading (NASDAQ) at $3.29 or down 3 cents per share.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment